OneAscent Wealth Management LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

by · The Cerbat Gem

OneAscent Wealth Management LLC purchased a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 452 shares of the company’s stock, valued at approximately $400,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Meeder Advisory Services Inc. boosted its position in shares of Eli Lilly and Company by 2.9% during the 3rd quarter. Meeder Advisory Services Inc. now owns 15,761 shares of the company’s stock valued at $13,963,000 after acquiring an additional 438 shares during the last quarter. Semus Wealth Partners LLC raised its holdings in Eli Lilly and Company by 27.2% during the 3rd quarter. Semus Wealth Partners LLC now owns 3,101 shares of the company’s stock valued at $2,747,000 after buying an additional 664 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter valued at $30,000. Napa Wealth Management raised its holdings in Eli Lilly and Company by 379.2% during the 3rd quarter. Napa Wealth Management now owns 3,048 shares of the company’s stock valued at $2,700,000 after buying an additional 2,412 shares during the period. Finally, Cassaday & Co Wealth Management LLC raised its holdings in Eli Lilly and Company by 2.1% during the 3rd quarter. Cassaday & Co Wealth Management LLC now owns 5,570 shares of the company’s stock valued at $4,935,000 after buying an additional 113 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. Barclays decreased their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a report on Monday, September 16th. Guggenheim increased their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,007.94.

Check Out Our Latest Research Report on LLY

Eli Lilly and Company Stock Down 4.2 %

Shares of LLY traded down $31.31 during midday trading on Monday, reaching $714.89. 1,229,976 shares of the stock were exchanged, compared to its average volume of 3,129,583. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company’s 50 day moving average is $882.65 and its two-hundred day moving average is $871.04. The company has a market capitalization of $678.66 billion, a P/E ratio of 80.67, a PEG ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the company posted $0.10 EPS. Eli Lilly and Company’s quarterly revenue was up 20.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s payout ratio is 56.22%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also